Drugs / Measles, Mumps, Rubella (MMR) Combined Live Attenuated Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06442449 | Aug 2024 → Sep 2025 | poliomyelitis | Sinovac Biotech Co., Ltd | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles, Mumps, Rubella (MMR) Combined Live Attenuated Vaccine | “Measles, Mumps, Rubella (MMR) Combined Live Attenuated Vaccine” NCT06442449 ↗ |
| Known as | MMR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06442449 ↗ |
| Modality | Vaccine | “Measles, Mumps, Rubella (MMR) Combined Live Attenuated Vaccine” NCT06442449 ↗ |